Tanya Dorff, MD, on the future of cellular immunotherapy versus checkpoint inhibition in mPC

Tanya Dorff, MD, on the future of cellular immunotherapy versus checkpoint inhibition in mPC

Dr. Dorff, Associate Clinical Professor, City of Hope, shares thoughts on the future of cellular immunotherapy versus checkpoint inhibition in metastatic prostate cancer